Nutriband (NASDAQ:NTRB – Get Free Report) and ProPhase Labs (NASDAQ:PRPH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.
Earnings and Valuation
This table compares Nutriband and ProPhase Labs”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nutriband | $2.04 million | 41.31 | -$8.23 million | ($0.53) | -13.08 |
| ProPhase Labs | $5.05 million | 0.05 | -$53.36 million | ($2.25) | -0.01 |
Analyst Ratings
This is a breakdown of current recommendations for Nutriband and ProPhase Labs, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
| ProPhase Labs | 1 | 0 | 0 | 0 | 1.00 |
Volatility and Risk
Nutriband has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500.
Profitability
This table compares Nutriband and ProPhase Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nutriband | -430.35% | -109.07% | -95.54% |
| ProPhase Labs | -825.01% | -482.05% | -88.90% |
Institutional & Insider Ownership
19.7% of Nutriband shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Nutriband beats ProPhase Labs on 9 of the 12 factors compared between the two stocks.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
